<DOC>
	<DOCNO>NCT00440752</DOCNO>
	<brief_summary>The newly introduce antimalarial drug artemether-lumefantrine currently recommend second line antimalarial Sudan . Recurrent infection treatment drug associate selection certain gene malaria parasite . However information association Sudan.This study go look genetics resistance artemether-lumefantrine .</brief_summary>
	<brief_title>The Impact Artemether-Lumefantrine Genes Associated With Antimalarial Resistance</brief_title>
	<detailed_description>In Sudan current treatment protocol include two artemisinin combination ( ACT ) ; artesunate + sulphadoxine/pyrimethamine ( AS/SP ) first line artemether-lumefantrine ( AL ) second line . This protocol implement 2004 , since various study report high efficacy combination ( e.g . Adam et al. , 2005 ; Elamin et al. , 2005 ; Mohamed et al. , 2006 ) . However , report impact combination drug resistance marker Sudan . Data African country show AL selects certain allele pfmdr-1 gene ( Sisowath et al. , 2005 , Dokomajilar et al. , 2006 ; Humphreys et al. , 2007 ) , impact prevalence different pfcrt pfmdr-1alleles remain unclear . It essential monitor ACT efficacy addition identify molecular marker associate response different drug facilitate epidemiological survey evidence base decision making . Recent work The Gambia suggest transmission-related endpoint , emergence gametocyte treatment , may better indicator emerge drug resistance ( Hallett et al. , 2006 ) . The aim propose study examine impact treatment artemether-lumefantrine ( AL ) alleles pfcrt pfmdr-1 P. falciparum isolate area mark seasonal transmission eastern Sudan . Most study resistance marker measure marker prevalence DNA amplification , also investigate gene expression use quantitative amplification mRNA encode pfcrt pfmdr-1 . The impact genotype gene expression level treatment outcome , emergence density peripheral gametocyte examine .</detailed_description>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Antimalarials</mesh_term>
	<criteria>Monoinfection P. falciparum microscopy . Initial parasite density 1000 100,000 asexual parasites/Âµl . Absence general danger sign sign severe complicate falciparum malaria accord WHO definition . Informed consent provide patient parent/guardian . Pregnancy Infection mix Plasmodium sp . Signs severe malaria danger sign Refusal provide consent</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Artemether-lumefantrine</keyword>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>drug resistance gene</keyword>
</DOC>